{"DataElement":{"publicId":"2775979","version":"1","preferredName":"Intravenous Route of Administration Immunoglobulin Therapeutic Procedure Indication Type","preferredDefinition":"A description of the indication(s) for the supplemental intravenous immunoglobulin therapy.","longName":"IRA_IMG_THRP_IND_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2775977","version":"1","preferredName":"Intravenous Route of Administration Immunoglobulin Therapeutic Procedure Indication","preferredDefinition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index._Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","longName":"IRA_IMG_THRP_IND","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2758913","version":"1","preferredName":"Intravenous Route of Administration Immunoglobulin Therapeutic Procedure","preferredDefinition":"Administration within or into a vein or veins.:Glycoproteins present in the blood (ANTIBODIES) and in other tissue. They are classified by structure and activity into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M).:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C38276:C572:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Immunoglobulin","conceptCode":"C572","definition":"Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F56720C-46E7-46F3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-10","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-06-10","modifiedBy":"ONEDATA","dateModified":"2008-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2193066","version":"1","preferredName":"Indication","preferredDefinition":"A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","longName":"C41184","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indication","conceptCode":"C41184","definition":"A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAA83722-8121-511A-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-12-08","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"554931A3-B484-41E3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-25","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2775122","version":"1","preferredName":"Immunoglobulin Therapeutic Procedure Indication Type","preferredDefinition":"Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication)._Type; a subdivision of a particular kind of thing.","longName":"IMG_TH_PR_IND_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"86","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Prophylaxis for low IgG with no active infection","valueDescription":"Preventive Intervention Low IgG No Active Infection","ValueMeaning":{"publicId":"2775126","version":"1","preferredName":"Preventive Intervention Low IgG No Active Infection","longName":"2775126","preferredDefinition":"An attempt to prevent disease.: A minimum level or position or degree; less than normal in degree or intensity or amount.: An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.: The non-affirmative response to a question.: Taking part in an activity.: A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Low","conceptCode":"C54722","definition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"IgG","conceptCode":"C568","definition":"An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Active","conceptCode":"C45329","definition":"Exerting influence or producing an effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Infectious Disorder","conceptCode":"C26726","definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D70714-FCC8-320D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7660CD09-7EA8-13C8-E040-BB89AD433817","beginDate":"2008-08-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-20","modifiedBy":"ONEDATA","dateModified":"2009-10-20","deletedIndicator":"No"},{"value":"Treatment for infection with low IgG","valueDescription":"Therapeutic Procedure Infection Low IgG","ValueMeaning":{"publicId":"2775124","version":"1","preferredName":"Therapeutic Procedure Infection Low IgG","longName":"2775124","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact. -- 2003: A minimum level or position or degree; less than normal in degree or intensity or amount.: An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Infectious Disorder","conceptCode":"C26726","definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Low","conceptCode":"C54722","definition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"IgG","conceptCode":"C568","definition":"An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D70714-FC74-320D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7660CD09-7EBC-13C8-E040-BB89AD433817","beginDate":"2008-08-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-20","modifiedBy":"ONEDATA","dateModified":"2009-10-20","deletedIndicator":"No"},{"value":"Treatment for respiratory syncytial virus (RSV) infection","valueDescription":"Therapeutic Procedure Respiratory Syncytial Virus","ValueMeaning":{"publicId":"2775123","version":"1","preferredName":"Therapeutic Procedure Respiratory Syncytial Virus","longName":"2775123","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: A virus that causes respiratory infections with cold-like symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Human Respiratory Syncytial Virus","conceptCode":"C14267","definition":"A negative-sense, enveloped RNA virus. The virion is variable in shape and size with an average diameter of between 120 and 300 nm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D70714-FC4A-320D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54D70714-FC63-320D-E044-0003BA3F9857","beginDate":"2008-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"COOPERM","dateModified":"2008-08-19","deletedIndicator":"No"},{"value":"Treatment for CMV infection","valueDescription":"Therapeutic Procedure Cytomegalovirus","ValueMeaning":{"publicId":"2775125","version":"1","preferredName":"Therapeutic Procedure Cytomegalovirus","longName":"2775125","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: A genus of the family herpesviridae, subfamily betaherpesvirinae, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytomegalovirus","conceptCode":"C14196","definition":"A genus of the family herpesviridae, subfamily betaherpesvirinae, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D70714-FC9C-320D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"54D70714-FCB5-320D-E044-0003BA3F9857","beginDate":"2008-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"COOPERM","dateModified":"2008-08-19","deletedIndicator":"No"},{"value":"Other Indication","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5D30CE-5544-1A28-E044-0003BA3F9857","beginDate":"2008-11-10","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-10","modifiedBy":"NYCHM","dateModified":"2008-11-10","deletedIndicator":"No"},{"value":"Prophylaxis for cytomegalovirus infection","valueDescription":"Preventive Intervention Cytomegalovirus","ValueMeaning":{"publicId":"2775127","version":"1","preferredName":"Preventive Intervention Cytomegalovirus","longName":"2775127","preferredDefinition":"An attempt to prevent disease.: A genus of the family herpesviridae, subfamily betaherpesvirinae, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytomegalovirus","conceptCode":"C14196","definition":"A genus of the family herpesviridae, subfamily betaherpesvirinae, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D70714-FCF0-320D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"865371D1-081A-541B-E040-BB89AD433026","beginDate":"2008-08-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-05-11","modifiedBy":"ONEDATA","dateModified":"2010-05-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2775121","version":"1","preferredName":"Immunoglobulin Therapeutic Procedure Indication Type","preferredDefinition":"Glycoproteins present in the blood (ANTIBODIES) and in other tissue. They are classified by structure and activity into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M).:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).:Type; a subdivision of a particular kind of thing.","longName":"C572:C49236:C41184:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunoglobulin","conceptCode":"C572","definition":"Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Indication","conceptCode":"C41184","definition":"A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D70714-FC21-320D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"ONEDATA","dateModified":"2008-08-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D70714-FC32-320D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"NYCHM","dateModified":"2010-11-23","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964902","version":"1","longName":"2100r1: 100 Days Post-HSCT Data","context":"NHLBI"},{"publicId":"2964922","version":"1","longName":"2200r1: 6 Month to 2 Year Post-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedProcedure:reasonCode","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the indication(s) for","type":"Preferred Question Text","description":"Specify the indication(s) for the supplemental intravenous immunoglobulin therapy:","url":null,"context":"NHLBI"},{"name":"What is the indication(s) for the supplemental intravenous immunoglobulin therapy:","type":"Alternate Question Text","description":"What is the indication(s) for the supplemental intravenous immunoglobulin therapy:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2775979","type":"BRIDG Mapping Path","description":"PerformedProcedure.reasonCode WHERE PerformedProcedure > DefinedProcedure.nameCode = \"Perform Therapeutic Procedure\"  AND DefinedActivity.nameCode = \"Administer intravenous immunoglobulin \"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"55488995-0C7A-496B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-25","modifiedBy":"ALEYR","dateModified":"2019-04-07","changeDescription":". System generated def displayed as alt def. AK 6/10/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}